BridgeBio Pharma, Inc. (BBIO): debt financing — BridgeBio secures $500M royalty financing for acoramidis and $450M term loan, repays existing debt

BridgeBio Pharma, Inc.

Funding Agreement: $500M from LSI/CPPIB upon FDA approval of acoramidis; 5% royalty on global net sales, cap $950M.
Financing Agreement: $450M initial term loan funded (up to $300M incremental) from Blue Owl; SOFR+6.75% or base+5.75% interest; matures Jan 17, 2029.
Existing $450M loan from Nov 2021 repaid and terminated using initial term loan proceeds and cash on hand.
Minimum cash covenant of $70M; prepayment fees up to 3% plus make-whole; two springing maturities tied to convertible notes.
Funding terminates if FDA approval of acoramidis does not occur by May 15, 2025, with no penalty.

Key facts

Extracted from this filing and checked against the source text.

Debt Financings SEC 8-K Item 2.03/2.04 confidence 0.95

BridgeBio Pharma, Inc. incurred term loan of $450,000,000 with Blue Owl Capital Corporation, as administrative agent at Term SOFR plus 6.75% maturing January 17, 2029.

Instrument: term loan
Principal: $450,000,000
Counterparty: Blue Owl Capital Corporation, as administrative agent
Rate: Term SOFR plus 6.75%
Maturity: January 17, 2029
Event: incurrence

Exact text from the filing

On the Closing Date, the Company entered into a Financing Agreement (the “Financing Agreement”) with certain of its subsidiaries party thereto as guarantors, the lenders party thereto (the “Lenders”) and Blue Owl Capital Corporation, as administrative agent for the Lenders (the “Administrative Agent”). Pursuant to the terms and conditions of the Financing Agreement, the Lenders have agreed to extend a senior secured credit facility to the Company in an aggregate principal amount of up to $750,000,000, comprised of (i) an initial term loan in an aggregate principal amount of $450,000,000 (the “Initial Term Loan”)

View on SEC.gov

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.95

BridgeBio Pharma, Inc. entered into Funding Agreement with LSI Financing 1 Designated Activity Company and CPPIB Credit Europe S.à r.l. valued at $500,000,000 (effective 2024-01-17).

Action: entry
Counterparty: LSI Financing 1 Designated Activity Company and CPPIB Credit Europe S.à r.l.
Value: $500,000,000
Effective: 2024-01-17

Exact text from the filing

entered into a Funding Agreement (the “Funding Agreement”) with LSI Financing 1 Designated Activity Company and CPPIB Credit Europe S.à r.l. (together, the “Purchasers”)

View on SEC.gov

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.95

BridgeBio Pharma, Inc. entered into Financing Agreement with Blue Owl Capital Corporation, as administrative agent valued at $750,000,000 (effective 2024-01-17).

Action: entry
Agreement: credit facility
Counterparty: Blue Owl Capital Corporation, as administrative agent
Value: $750,000,000
Effective: 2024-01-17

Exact text from the filing

On the Closing Date, the Company entered into a Financing Agreement (the “Financing Agreement”) with certain of its subsidiaries party thereto as guarantors, the lenders party thereto (the “Lenders”) and Blue Owl Capital Corporation, as administrative agent for the Lenders

View on SEC.gov

283 debt financings filed in the last 30 days. Browse all debt financings →

BridgeBio Pharma, Inc. filing history →

Source: SEC EDGAR

accession 0001140361-24-002636

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.